|
1
|
Lv H, Jiang L, Zhu M, Li Y, Luo M, Jiang
P, Tong S, Zhang H and Yan J: The genus Tripterygium: A
phytochemistry and pharmacological review. Fitoterapia.
137(104190)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liu L, Luo Y, Zhou M, Lu Y, Xing M, Ru Y,
Sun X, Chen X, Li S, Hong S, et al: Tripterygium agents for the
treatment of atopic eczema: A Bayesian analysis of randomized
controlled trials. Phytomedicine. 59(152914)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang D, Zhang H, Liang J, Wang H, Hua B,
Feng X, Gilkeson GS, Farge D, Shi S and Sun L: A long-term
follow-up study of allogeneic mesenchymal stem/stromal cell
transplantation in patients with drug-resistant systemic lupus
erythematosus. Stem Cell Reports. 10:933–941. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lü S, Wang Q, Li G, Sun S, Guo Y and Kuang
H: The treatment of rheumatoid arthritis using Chinese medicinal
plants: From pharmacology to potential molecular mechanisms. J
Ethnopharmacol. 176:177–206. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ramgolam V, Ang SG, Lai YH, Loh CS and Yap
HK: Traditional Chinese medicines as immunosuppressive agents. Ann
Acad Med Singap. 29:11–16. 2000.PubMed/NCBI
|
|
6
|
Jiang X, Huang XC, Ao L, Liu WB, Han F,
Cao J, Zhang DY, Huang CS and Liu JY: Total alkaloids of
Tripterygium hypoglaucum (levl.) Hutch inhibits tumor growth both
in vitro and in vivo. J Ethnopharmacol. 151:292–298.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yang YQ, Wu YF, Xu FF, Deng JB, Wu LL, Han
XD, Liang J, Guo DA and Liu B: Tripterygium glycoside fraction n2:
Alleviation of DSS-induced colitis by modulating immune homeostasis
in mice. Phytomedicine. 58(152855)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li JM, Jiang Q, Tang XP, Yang H and Zhou
ZQ: Study advances in regulation effect of Tripterygium
wilfordii and its extracts on innate immune system in
rheumatoid arthritis cases. Zhongguo Zhong Yao Za Zhi.
44:3384–3390. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
9
|
Liu L, Yan J, Shu JC and Liu JQ: Advance
on alkaloids from Tripterygium wilfordii and their
bioactivities. Nat Prod Res Dev. 31:2170–2181. 2019.
|
|
10
|
Lipsky PE and Tao XL: A potential new
treatment for rheumatoid arthritis: Thunder god vine. Semin
Arthritis Rheum. 26:713–723. 1997.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Brinker AM, Ma J, Lipsky PE and Raskin I:
Medicinal chemistry and pharmacology of genus Tripterygium
(Celastraceae). Phytochemistry. 68:732–766. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nong C, Wang XZ, Jiang ZZ and Zhang LY:
Progress of effect and mechanisms of Tripterygium wilfordii
on immune system. Zhongguo Zhong Yao Za Zhi. 44:3374–3383.
2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
13
|
Wu X, Huang W, Guo B, Si J and Zhang J:
Determination of contents of tripterine in Tripterygii
preparations. Zhongguo Zhong Yao Za Zhi. 34:836–838.
2009.PubMed/NCBI(In Chinese).
|
|
14
|
Li H, Fan Y, Yang F, Zhao L and Cao B: The
coordinated effects of Apatinib and Tripterine on the
proliferation, invasiveness and apoptosis of human hepatoma Hep3B
cells. Oncol Lett. 16:353–361. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen YW, Lin GJ, Hueng DY, Huang SH, Chia
WT, Shieh YS, Ma KH and Sytwu HK: Enhanced anti-tumor activity of
triptolide in combination with irradiation for the treatment of
oral cancer. Planta Med. 80:255–261. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xiong Y, Yan Y and Li Y: RETRACTED:
Tripterine alleviates LPS-induced inflammatory injury by
up-regulation of miR-146a in HaCaT cells. Biomed Pharmacother.
105:798–804. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li X, Lu Q, Xie W, Wang Y and Wang G:
Anti-tumor effects of triptolide on angiogenesis and cell apoptosis
in osteosarcoma cells by inducing autophagy via repressing
Wnt/β-catenin signaling. Biochem Biophys Res Commun. 496:443–449.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen Y, Qu D, Fu R, Guo M, Qin Y, Guo J
and Chen Y: A Tf-modified tripterine-loaded coix seed oil
microemulsion enhances anti-cervical cancer treatment. Int J
Nanomedicine. 13:7275–7287. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zuo A, Zhao P, Zheng Y, Hua H and Wang X:
Tripterine inhibits proliferation, migration and invasion of breast
cancer MDA-MB-231 cells by up-regulating microRNA-15a. Biol Chem.
400:1069–1078. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yuan L, Liu C, Chen Y, Zhang Z, Zhou L and
Qu D: Antitumor activity of tripterine via cell-penetrating
peptide-coated nanostructured lipid carriers in a prostate cancer
model. Int J Nanomedicine. 8:4339–4350. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jin C, He X, Zhang F, He L, Chen J, Wang
L, An L and Fan Y: Inhibitory mechanisms of celastrol on human
liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4. Xenobiotica.
45:571–577. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sun M, Tang Y, Ding T, Liu M and Wang X:
Inhibitory effects of celastrol on rat liver cytochrome P450 1A2,
2C11, 2D6, 2E1 and 3A2 activity. Fitoterapia. 92:1–8.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang YS, Tu YY, Gao XC, Yuan J, Li G,
Wang L, Deng JP, Wang Q and Ma RM: Strong inhibition of celastrol
towards UDP-glucuronosyl transferase (UGT) 1A6 and 2B7 indicating
potential risk of UGT-based herb-drug interaction. Molecules.
17:6832–6839. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhao Q, Liu F, Cheng Y, Xiao XR, Hu DD,
Tang YM, Bao WM, Yang JH, Jiang T, Hu JP, et al: Celastrol protects
from cholestatic liver injury through modulation of SIRT1-FXR
signaling. Mol Cell Proteomics. 18:520–533. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hua H, Zhang Y, Zhao F, Chen K, Wu T, Liu
Q, Huang S, Zhang A and Jia Z: Celastrol inhibits intestinal lipid
absorption by reprofiling the gut microbiota to attenuate high-fat
diet-induced obesity. iScience. 24(102077)2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lindholm A, Henricsson S and Dahlqvist R:
The effect of food and bile acid administration on the relative
bioavailability of cyclosporin. Br J Clin Pharmacol. 29:541–548.
1990.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gupta SK, Manfro RC, Tomlanovich SJ,
Gambertoglio JG, Garovoy MR and Benet LZ: Effect of food on the
pharmacokinetics of cyclosporine in healthy subjects following oral
and intravenous administration. J Clin Pharmacol. 30:643–653.
1990.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang X, Xu L, Ren H, Li Z, Sun C and Zhang
Z: The effect of multi-glycosides of Tripterygium wilfordii
Hook f. (GTW) on the survival time of cardiac allografts in rats.
Chin Med Sci J. 7:232–234. 1992.PubMed/NCBI
|
|
29
|
Zhang LL and Sun JH: Synergistic effects
of Tripterygium wilfordii polyglycosides and cyclosporine A
in rat heart transplantation. Chin J Exp Surg. 23–24. 2001.
|
|
30
|
Li J and Hao J: Treatment of
neurodegenerative diseases with bioactive components of
Tripterygium wilfordii. Am J Chin Med. 47:769–785.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang HL, Jiang Q, Feng XH, Zhang HD, Ge L,
Luo CG, Gong X and Li B: Tripterygium wilfordii Hook F
versus conventional synthetic disease-modifying anti-rheumatic
drugs as monotherapy for rheumatoid arthritis: A systematic review
and network meta-analysis. BMC Complement Altern Med.
16(215)2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang XB, Dai EL, Xue GZ and Ma RL: A
PRISMA-compliant systematic review and network meta-analysis on the
efficacy between different regimens based on Tripterygium
wilfordii Hook F in patients with primary nephrotic syndrome.
Medicine (Baltimore). 97(e11282)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yu CP, Lin HJ, Lin SP, Shia CS, Chang PH,
Hou YC and Hsieh YW: Rhubarb decreased the systemic exposure of
cyclosporine, a probe substrate of P-glycoprotein and CYP 3A.
Xenobiotica. 46:677–682. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Dupuis R, Yuen A and Innocenti F: The
influence of UGT polymorphisms as biomarkers in solid organ
transplantation. Clin Chim Acta. 413:1318–1325. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yigitaslan S, Erol K and Cengelli C: The
effect of P-glycoprotein inhibition and activation on the
absorption and serum levels of cyclosporine and tacrolimus in rats.
Adv Clin Exp Med. 25:237–242. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Goldberg H, Ling V, Wong PY and Skorecki
K: Reduced cyclosporin accumulation in multidrug-resistant cells.
Biochem Biophys Res Commun. 152:552–558. 1988.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fahr A: Cyclosporin clinical
pharmacokinetics. Clin Pharmacokinet. 24:472–495. 1993.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Huang X, Zhang R, Yang T, Wei Y, Yang C,
Zhou J, Liu Y and Shi S: Inhibition effect of
epigallocatechin-3-gallate on the pharmacokinetics of calcineurin
inhibitors, tacrolimus, and cyclosporine A, in rats. Expert Opin
Drug Metab Toxicol. 17:121–134. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yang T, Liu Y, Huang X, Zhang R, Yang C,
Zhou J, Zhang Y, Wan J and Shi S: Quercetin-3-O-β-D-glucoside
decreases the bioavailability of cyclosporin A through regulation
of drug metabolizing enzymes, transporters and nuclear receptors in
rats. Mol Med Rep. 18:2599–2612. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29(e45)2001.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Hou YC, Lin SP and Chao PDL: Liquorice
reduced cyclosporine bioavailability by activating P-glycoprotein
and CYP 3A. Food Chem. 135:2307–2312. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Manikandan P and Nagini S: Cytochrome P450
structure, function and clinical significance: A review. Curr Drug
Targets. 19:38–54. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Meier-Abt F, Faulstich H and Hagenbuch B:
Identification of phalloidin uptake systems of rat and human liver.
Biochim Biophys Acta. 1664:64–69. 2004.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Pan G: Roles of hepatic drug transporters
in drug disposition and liver toxicity. Adv Exp Med Biol.
1141:293–340. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Müller J, Keiser M, Drozdzik M and Oswald
S: Expression, regulation and function of intestinal drug
transporters: An update. Biol Chem. 398:175–192. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ivanyuk A, Livio F, Biollaz J and Buclin
T: Renal drug transporters and drug interactions. Clin
Pharmacokinet. 56:825–892. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Li L, Yao QQ, Xu SY, Hu HH, Shen Q, Tian
Y, Pan LY, Zhou H, Jiang HD, Lu C, et al: Cyclosporin A affects the
bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
Eur J Pharm Biopharm. 88:759–767. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Xia CQ, Liu N, Miwa GT and Gan LS:
Interactions of cyclosporin a with breast cancer resistance
protein. Drug Metab Dispos. 35:576–582. 2007.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Akashi M, Tanaka A and Takikawa H: Effect
of cyclosporin A on the biliary excretion of cholephilic compounds
in rats. Hepatol Res. 34:193–198. 2006.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Tang W, Stearns RA, Chen Q, Bleasby K,
Teffera Y, Colletti A, Hafey M, Evers R, Dean DC, Magriotis PA, et
al: Importance of mechanistic drug metabolism studies in support of
drug discovery: A case study with an N-sulfonylated dipeptide VLA-4
antagonist in rats. Xenobiotica. 38:223–237. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Xu C, Li CYT and Kong ANT: Induction of
phase I, II and III drug metabolism/transport by xenobiotics. Arch
Pharm Res. 28:249–268. 2005.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Venkataramanan R, Perez HD, Schwinghammer
T, Burckart GJ, Ptachcinski RJ, Van Thiel DH and Starzl TE: Effect
of bile on cyclosporine absorption in dogs. Res Commun Chem Pathol
Pharmacol. 53:137–140. 1986.PubMed/NCBI
|
|
53
|
Takaya S, Iwatsuki S, Noguchi T, Koie H,
Zaghloul I, Venkataramanan R and Starzl TE: The influence of liver
dysfunction on cyclosporine pharmacokinetics-a comparison between
70 per cent hepatectomy and complete bile duct ligation in dogs.
Jpn J Surg. 19:49–56. 1989.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Meier PJ and Stieger B: Bile salt
transporters. Annu Rev Physiol. 64:635–661. 2002.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Stieger B: The role of the
sodium-taurocholate cotransporting polypeptide (NTCP) and of the
bile salt export pump (BSEP) in physiology and pathophysiology of
bile formation. Handb Exp Pharmacol. 205–259. 2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Katafuchi T and Makishima M: Molecular
basis of bile acid-FXR-FGF15/19 signaling axis. Int J Mol Sci.
23(6046)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lindholm A: Factors influencing the
pharmacokinetics of cyclosporine in man. Ther Drug Monit.
13:465–477. 1991.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F
and Wu W: Enhanced oral bioavailability of cyclosporine A by
liposomes containing a bile salt. Int J Nanomedicine. 6:965–974.
2011.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Fan J, Chen L, Lu X, Li M and Zhu L: The
pharmacokinetic prediction of cyclosporin A after coadministration
with Wuzhi capsule. AAPS PharmSciTech. 20(247)2019.PubMed/NCBI View Article : Google Scholar
|
